Idarubicin
- Generic Name
- Idarubicin
- Brand Names
- Idamycin
- Drug Type
- Small Molecule
- Chemical Formula
- C26H27NO9
- CAS Number
- 58957-92-9
- Unique Ingredient Identifier
- ZRP63D75JW
- Background
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
- Indication
For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
- Associated Conditions
- Acute Myeloid Leukemia
- Associated Therapies
- -
Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Target Recruit Count
- 18
- Registration Number
- NCT01040559
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de DIJON, Dijon, Burgundy, France
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
- Conditions
- Interventions
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2018-10-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT01025154
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 470
- Registration Number
- NCT00967057
- Locations
- 🇬🇧
Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧Christie Hospital, Manchester, England, United Kingdom
🇦🇺Women's and Children's Hospital, North Adelaide, South Australia, Australia
Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Valerio Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT00878722
- Locations
- 🇫🇷
Hôpital St. Louis, Paris, France
🇩🇪Uniklinik Homburg, Homburg, Germany
🇩🇪Uni Hospital Marburg, Marburg, Germany
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2022-10-25
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 106
- Registration Number
- NCT00866918
- Locations
- 🇺🇸
Overlook Hospital, Summit, New Jersey, United States
🇺🇸Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 115
- Registration Number
- NCT00840177
- Locations
- 🇺🇸
Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Genesee Hematology Oncology PC, Flint, Michigan, United States
🇺🇸Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
- Conditions
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2012-07-20
- Target Recruit Count
- 114
- Registration Number
- NCT00838240
- Locations
- 🇧🇪
Institut Jules Bordet, Brussel, Belgium
🇮🇹Azienda Ospedallera Universitaria - Policlinico Tor Vergata, Roma, Italy
🇮🇹Univesita Degli Studi "La Sapienza", Roma, Italy
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2020-12-22
- Target Recruit Count
- 51
- Registration Number
- NCT00831766
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Cleveland Clinic - Taussig Cancer Institute, Cleveland, Ohio, United States
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1Myelodysplastic Syndrome With Excess Blastst(8;21)High Risk Myelodysplastic SyndromeInv(16)t(16;16)Untreated Adult Acute Myeloid Leukemiade Novo Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 270
- Registration Number
- NCT00801489
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
- Conditions
- Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myelomonocytic Leukemia (M4)Childhood Acute Eosinophilic LeukemiaChildhood Acute Erythroleukemia (M6)
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00666588
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.